Control of severe pain with sustained-release morphine tablets v. oral morphine solution

Area of Science:

• Pharmacology
• Pain Management
• Clinical Trials

Background:

• Chronic severe pain management often requires frequent dosing.
• Sustained-release morphine sulfate tablets (MSC) offer a potential alternative to traditional morphine solutions.
• Optimizing pain control while minimizing patient burden is a key clinical goal.

Purpose of the Study:

• To compare the efficacy and tolerability of sustained-release morphine sulfate tablets (MSC) administered every 12 hours versus morphine sulfate solution (MSS) administered every 4 hours in patients with chronic severe pain.
• To evaluate patient preference and side effect profiles between the two morphine formulations.

Main Methods:

• A randomized, double-blind, crossover trial involving 17 patients with chronic severe pain.
• Patients received 10 days of therapy with either MSC (every 12 hours) or MSS (every 4 hours), followed by 10 days of the alternative formulation.
• Pain scores (visual analogue scale), tiredness, nausea, and supplemental morphine use were assessed.

Main Results:

• Both MSC and MSS provided effective pain control with minimal side effects.
• No significant differences were observed in visual analogue scale pain scores, tiredness, nausea, or supplemental morphine requirements between the two formulations.
• Plasma morphine concentrations tended to be higher with MSC, and the study had 89% power to detect significant differences in pain scores.

Conclusions:

• An individualized, twice-daily regimen of sustained-release morphine sulfate tablets (MSC) is as effective as a every 4-hour regimen of morphine sulfate solution (MSS) for managing severe chronic pain.
• The twice-daily MSC regimen offers significant advantages in convenience, uninterrupted sleep, and potentially reduced medication errors and noncompliance.
• MSC represents a viable and convenient option for long-term pain management.